TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20883054
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide conjugate vaccine Prevenar 13 (PCV13)
Study: 20883054
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PCV13
Study: 7673497
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (nontreated)
Study: 6116607
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg plus whisky 100 ml
Study: 27880064
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioural Therapy (Group-CBT) for 8 weeks
Study: 25935314
Drug: Acceptance &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance & Commitment group Therapy (ACT-G), n=63
Study: 21362011
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene protocol implemented in 7 nursing homes
Study: 19761353
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral lamivudine 100 mg/day before and until at least 6 months after transplantation
Study: 19761353
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and AHSCT without lamivudine (historical control group)
Study: 19761353
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral lamivudine 100 mg/day
Study: 18688944
Drug: Azithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1000 mg) plus loperamide
Study: 18688944
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg) plus loperamide
Study: 24278400
Drug: Azithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1000 mg)
Study: 15318711
Drug: 4 fractions
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 fractions of 6.5 Gy each (overall dosage‐‐26 Gy) (2 fractions per week)
Study: 15318711
Drug: 5 fractions
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 fractions of 6.5 Gy each (overall dosage‐‐32.5 Gy) (2 fractions per week)
Study: 15318711
Drug: 4 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 daily fractions of 6.5 Gy each (overall dosage‐‐26 Gy)
Study: 15318711
Drug: 23 fractions
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 fractions (overall dosage‐‐46 Gy) (5 weekly fractions)
Study: 15318711
Drug: Standard low‐dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low‐dosage fractionated irradiation
Study: 9763719
Drug: Blister packaging
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blister packaging of antimalarial drugs
Study: 9763719
Drug: Traditional means
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional means of dispensing antimalarial drugs (paper envelope)
Study: 7512805
Drug: Antihistamine treatment
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine treatment with dimetindene (0.2 mg/kg) and ranitidine (1.25 mg/kg)
Study: 26211735
Drug: 2% lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lavender essential oil via inhalation for 15 days
Study: 26211735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhalation of lavender essential oil)
Study: 19671398
Drug: Healthy school
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy school meal (25-30% of daily caloric intake) for two months
Study: 2577280
Drug: Timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10 mg b.i.d. for 5 days)
Study: 2577280
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg b.i.d. for 5 days)
Study: 30720034
Drug: Daily fresh
Normalized name: Vagisil Odor Block Daily Freshening Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fresh pear consumption (2 medium-sized pears per day)
Study: 26034956
Drug: Bundled intervention
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bundled intervention including mupirocin intranasally twice daily for up to 5 days, chlorhexidine-gluconate bathing for up to 5 days, and perioperative prophylaxis with vancomycin and cefazolin or cefuroxime for MRSA carriers; cefazolin or cefuroxime for others.
Study: 12063773
Drug: Lovastatin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (up to 40 mg/day)
Study: 9304634
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Study: 9304634
Drug: 7 ml
Normalized name: ethanol 7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Study: 8141715
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin with streptokinase (SK)
Study: 8141715
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin with streptokinase (SK)
Study: 2896506
Drug: Propranolol 2
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 2 X 40 mg p.o.
Study: 2896506
Drug: Betaxolol (Kerlone)
Normalized name: betaxolol hydrochloride Oral Tablet [Kerlone]
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol (Kerlone) 20 mg p.o.
Study: 30320560
Drug: Pre-CAS group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-CAS group (300 mg of clopidogrel before stenting)
Study: 30320560
Drug: Post-CAS group
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-CAS group (300 mg of clopidogrel after stenting)
Study: 29928776
Drug: Weight-specified dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-specified dose of alcohol (0.7 g alcohol/kg body weight)
Study: 22119513
Drug: E2 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (0.05 or 0.1 mg)
Study: 18844269
Drug: 0.6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 ml of a solution containing 30 units botulinum toxin
Study: 18844269
Drug: 0.6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 ml saline (placebo)
Study: 15031571
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nifedipine GITS
Study: 11522047
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg four times daily as a loading dose)
Study: 2737789
Drug: EpiDx (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiDx (720 mg/m2, 60 mg/m2 every 3 weeks)
Study: 2737789
Drug: Doxorubicin (Dx)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (Dx) (540 mg/m2, 60 mg/m2 every 3 weeks)
Study: 19083556
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg, twice daily in addition to 5‐mg hydrocodone tablets as needed
Study: 19083556
Drug: 5‐mg hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg hydrocodone tablets as needed
Study: 16868063
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg, orally, twice a day)
Study: 16868063
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg, orally, twice a day)
Study: 16868063
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and flutamide
Study: 9832970
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25, and 0.5 mg/70 kg)
Study: 22791533
Drug: Weekly direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly direct observation with formal feedback (DO-FF)
Study: 18194384
Drug: Single-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose lenograstim (5 microg per kg once daily)
Study: 18194384
Drug: Split-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose lenograstim (2.5 microg per kg twice daily)
Study: 15993933
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg/day) for 3 months prior to surgery
Study: 12847809
Drug: Kan-Yang tablets
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kan-Yang tablets
Study: 10228142
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via Turbuhaler (100 microgram per inhalation)
Study: 10228142
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via pMDI (100 microgram per inhalation)
Study: 8568123
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 2.4 mg/day, administered through a pressurized metered-dose inhaler for 4 weeks
Study: 8568123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as no treatment or placebo during the study)
Study: 4043476
Drug: Combined UVB-UVA
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined UVB-UVA treatment
Study: 24154932
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily and low-fat diet
Study: 18626299
Drug: ACE therapy
Normalized name: Salicylic Acid 0.5 g in 100 mL TOPICAL LIQUID [KOCOSTAR FACE THERAPY ACNE TREATMENT CREAM TO PATCH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE therapy in addition to treatment as usual
Study: 18626299
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy in addition to treatment as usual
Study: 17472487
Drug: Elixir composed
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir composed with air-dried C. papaya seeds and honey (CPH)
Study: 14679383
Drug: 1-month isoflavone
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month isoflavone supplementation (86 mg/day red clover-derived isoflavones)
Study: 10783653
Drug: Intravenous PGI2
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGI2
Study: 8439095
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment for children with serum FA levels lower than 3 ng/ml
Study: 8439095
Drug: Anticonvulsant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant therapy
Study: 3531452
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of gentamicin
Study: 3531452
Drug: Multiple-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose therapy of gentamicin
Study: 30884079
Drug: CNI-free immunosuppression
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free immunosuppression with everolimus (EVR), mycophenolic acid and steroids
Study: 30884079
Drug: Reduced-exposure CNI
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-exposure CNI with EVR and steroids
Study: 25336575
Drug: Topical brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide (Azopt)
Study: 23605805
Drug: Sublingual 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 10 mg Promptol™
Study: 23605805
Drug: Oral Inderal(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Inderal(®)
Study: 23605805
Drug: Sublingual 40
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 40 mg Promptol™
Study: 16290817
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy combined with vestibular rehabilitation (VR) program including psychoeducation, vestibular exercises, relaxation, and cognitive interventions.
Study: 12628840
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of CMF treatment
Study: 10692092
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with sequential transdermal 17beta‐oestradiol for 14 weeks and then medroxyprogesterone (MPA) for 14 days
Study: 8406404
Drug: Sublingual morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual morphine sulfate (10 mg)
Study: 8406404
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulfate (10 mg)
Study: 8406404
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulfate (10 mg)
Study: 3088973
Drug: D‐alpha‐tocopherol (268
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐alpha‐tocopherol (268 mg)
Study: 3088973
Drug: DL‐alpha‐tocopherol (364
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐alpha‐tocopherol (364 mg)
Study: 22442962
Drug: Antihypoxant reamberin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypoxant reamberin included in intensive treatment
Study: 11568553
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg intravenously
Study: 7933233
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (orchiectomy or estrogens)
Study: 7933233
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment and radical prostatectomy
Study: 31647577
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg DFN-15
Study: 29683391
Drug: Grape Seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Seed Extract (GSE) 300 mg
Study: 26979136
Drug: half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: half dose AV7909 on Days 0/14/28
Study: 26979136
Drug: BioThrax vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioThrax vaccine on Days 0/14/28
Study: 25494177
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat suture closure
Study: 22209361
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 2.5 mg
Study: 12137819
Drug: Urethral dilation
Normalized name: CATH,URETHRAL DILATION 7FR #G17844
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral dilation with Benique dilatators (maximal 21F) under intraurethral anesthesia, starting 10 days after initial DVIU, protocol: weekly for the first month, once after 3 and 6 months, then annually.
Study: 1944438
Drug: Acyclovir (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (20 mg/kg, orally, four times daily for five days)
Study: 6686118
Drug: beta-blockade (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockade (50 mg oral metoprolol or 40 mg oral propranolol, each twice per day)
Study: 23160696
Drug: 7.5 mg/ml
Normalized name: pectin 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/ml ropivacaine (group A, 42 patients)
Study: 23160696
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml levobupivacaine (group B, 44 patients)
Study: 17469891
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and acceptance and commitment therapy (ACT)
Study: 15660859
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation 4 mg/kg per day
Study: 15660859
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral iron supplementation)
Study: 3094411
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cromolyn
Study: 31526014
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (0.8 mSv)
Study: 31526014
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (4.2 mSv)
Study: 18088241
Drug: Lamivudine (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (previous treatment)
Study: 8113478
Drug: Reminiscence Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence Therapy (RT)
Study: 30993928
Drug: Endovascular intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endovascular intervention treatment
Study: 21196761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual allergy medication)
Study: 18070004
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) and bright-light therapy (1 hour of morning light exposure at > or = 2,500 lux)
Study: 16527014
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray (0.05% concentration, one spray in each nostril, three times a day for 5 days)
Study: 12866606
Drug: CI‐1023 (Ad(GV)VEGF121.10),
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI‐1023 (Ad(GV)VEGF121.10), a replication‐deficient adenovirus encoding human vascular endothelial growth factor isoform 121, administered via intramuscular injection (4 x 10(8) to 4 x 10(10) particle units)
Study: 9340057
Drug: Chemotherapy (Carboplatine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Carboplatine, Etoposide, Vincristine, 6 courses, 3-week basis)
Study: 9340057
Drug: Chemoradiotherapy (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (same chemotherapy regimen + primary site irradiation, total dose 40Gy)
Study: 8349471
Drug: Piroxicam FDDF
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam FDDF (40 mg in a single sublingual dose)
Study: 2882966
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (1000 mg, Pentasa)
Study: 26179482
Drug: Tofogliflozin 5
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 5 mg
Study: 26179482
Drug: Tofogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofogliflozin 2.5 mg
Study: 21441078
Drug: AZLI 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZLI 75 mg administered 3-times daily for 28 days
Study: 1905361
Drug: Minoxidil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (1 ml of a 2% solution)
Study: 1905361
Drug: Nitroglycerin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (2.5 gm of a 10% ointment)
Study: 31187674
Drug: Luo Han
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [eluo Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luo Han Guo decoction (30 mL administered starting 6 hours after surgery)
Study: 25559811
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with capecitabine and cisplatin (XP)
Study: 25559811
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (XPRT)
Study: 23567482
Drug: Preventive acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Study: 23567482
Drug: Preemptive acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Study: 23567482
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mL IV normal saline as placebo)
Study: 23567482
Drug: Preemptive acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive acetaminophen (15 mg/kg IV)
Study: 23567482
Drug: Preventive acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive acetaminophen (15 mg/kg IV)
Study: 22207070
Drug: rESWT in
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rESWT in spastic muscle + rESWT in antagonist muscle
Study: 19955891
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 3 microg/kg
Study: 19955891
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral pantoprazole 40 mg)
Study: 11245349
Drug: Aqueous oral
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous oral vitamin E supplementation for 6 weeks
Study: 9575674
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of local anesthetic
Study: 28253887
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (1-2 sessions of physiotherapy per week, hippotherapy, circuit training, and occupational therapy as necessary for 5 weeks)
Study: 24758776
Drug: Intraperitoneal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal lidocaine 50 mg/h (10 ml) once every hour